In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer - Full Text View

Purpose

The purpose of this research study is to determine whether we can purify and grow a population of cells from the participants blood (iNKT cells) and then safely give them back to the participant in increased numbers, and whether these cells will then stimulate the bodies own immune response against the cancer. These iNKT cells have been used in laboratory studies and information from these and other research studies suggest that increasing the number of these cells in the blood can stimulate the immune response against tumors.

Condition	Intervention	Phase
Malignant Melanoma	Biological: INKT Drug: GM-CSF	Phase 1


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	A Phase I Trial of in Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Carcinoid Tumor Neuroepithelioma

U.S. FDA Resources

Further study details as provided by Steven Balk, MD, Dana-Farber Cancer Institute:

Primary Outcome Measures:

To determine the feasibility of isolating and expanding in vitro autologous iNKT cells from cancer patients for therapeutic use. [ Time Frame: 2 years ]
To assess the safety of treatment with in vitro expanded autologous iNKT cells alone, and in conjunction with GM-CSF. [ Time Frame: 2 years ]

Secondary Outcome Measures:

To assess the biological activity of reinfused in vitro expanded autologous iNKT cells. [ Time Frame: 2 years ]
To assess the biological activity of reinfused in vitro expanded autologous iNKT cells in conjunction with GM-CSF. [ Time Frame: 2 years ]


Enrollment:	9
Study Start Date:	February 2008
Study Completion Date:	April 2015
Primary Completion Date:	August 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
GM-CSF +INKT INKT will be administered in 3 equal doses by intravenous infusion on days 1, 15 and 29. GM-CSF will be given subcutaneously once daily for 10 days beginning the second day of the second and third infusion	Biological: INKT Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29. Other Name: In vitro expanded autologous invariant natural killer T cells Drug: GM-CSF Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion

Detailed Description:

The first step in the study will be to collect iNKT cells from the participants peripheral blood. For this procedure an intravenous catheter will be used to remove the blood. The white blood cells will be removed from the blood and the red blood cells and plasma will be returned to the participant (leukopheresis).
We will then purify the iNKT cells from these collected white blood cells, and will grow them in culture plates in the lab under strictly controlled sterile conditions. This can take 4-6 weeks.
If we are successful in growing the iNKT cells to large enough numbers, they will be divided into 3 equal doses. Participants will receive one dose of these cells by intravenous infusion every 2 weeks or days 1, 15 and 29. A blood sample will be taken immediately before each infusion, and at 1 and 4 hours after each infusion. Participants will be asked to return for blood samples on day 2, 3, 4 and 8 after infusion.
The initial group of 3-6 participants will not receive any other therapy with the iNKT cell infusions. However, the subsequent group of 6 patients will in addition receive GM-CSF, which can further stimulate the immune system and may increase the effects of the iNKT cells. This medication is administered by subcutaneous injection and will be given daily for 10 days beginning the day of the second and third infusion.
Participants will be on this research study for about 14 weeks, which includes the time for the cell purification and culture, treatment, and follow-up observation.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Stage IV melanoma
ECOG Performance Status 0-1
Estimated life expectancy of 6 months or greater
18 years of age or older
Adequate renal, hepatic and hematological function as outlined in protocol
Adequate pulmonary and cardiac function as outlined in protocol
Prior therapies must be discontinued at least 4 weeks prior to the leukopheresis to obtain iNKT cells. This does not include palliative surgery or radiation therapy, which may be used prior to leukopheresis or during the interval between leukopheresis and iNKT cell reinfusion
Melanoma patients must not have brain metastases based on a negative MRI obtained within 4 weeks prior to screening, and must not have a history of brain metastases
No other significant medical, surgical or psychiatric condition that, in the judgment of the PI, would interfere with compliance to the protocol regimen

Exclusion Criteria:

Pregnant or nursing women
Active systemic infection, positive HIV, HBV, or HCV serology, or immune deficiency disease
Autoimmune disease that currently requires systemic therapy with immunosuppressive agents
Known hypersensitivity to GM-CSF or DMSO
Other active malignancy other than squamous cell or basal cell of the skin

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00631072

Locations


United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

Investigators


Principal Investigator:	Steven Balk, MD, PhD	Beth Israel Deaconess Medical Center
Principal Investigator:	F. Stephen Hodi, MD	Dana-Farber Cancer Institute

More Information


Responsible Party:	Steven Balk, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:	NCT00631072 History of Changes
Other Study ID Numbers:	06-432
Study First Received:	February 28, 2008
Last Updated:	June 7, 2017

Keywords provided by Steven Balk, MD, Dana-Farber Cancer Institute:


iNKT in vitro autologous iNKT

Additional relevant MeSH terms:


Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal	Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas

ClinicalTrials.gov processed this record on August 17, 2017